Sea Pharmaceuticals, LLC

Company

Developer of SPM-0404, an AMPA/kainate glutamate-receptor antagonist also pursued for epilepsy and sporadic ALS. In April 2025, selected Inotiv Inc. (NASDAQ: NOTV) to conduct IND-enabling preclinical studies and support Phase 1/1b pharmacokinetic work.